The company was incorporated in the year 2002 to market innovative drug delivery concepts in the international and domestic markets. The company was initially a pure marketing company having its products manufactured by loan licensees and then selling them in the international and domestic markets. The product range consists of a number of ‘Pharmaceutical Formulation Intermediates’ and a few finished pharmaceutical formulations. The PFIs are being marketed in the international market comprising mainly the Middle East and South America. The company exports approximately 90% of its product range to the Middle East, Africa, Singapore, Hong Kong, Pakistan, Bangladesh, South America, Iran, Guatemala and Russia.
It started manufacturing during the financial year 2009 /10. Pharmaceutical manufacturing is divided into two major stages: the production of the active ingredient or drug (primary processing, or manufacture) and secondary processing, the conversion of the active drugs into products suitable for administration. The company’s manufacturing process undertakes the second stage i.e. conversion of the active drugs into products suitable for administration. This allows the company to experiment with various drug delivery methods and produce a product that is superior due to its more acceptable delivery mechanism. The decision to go in for manufacturing was influenced by the following factors: Read more